Ewing's sarcoma of the femur. Prognosis in 69 patients treated by the CESS group

Toshifumi Ozaki*, Axel Hillmann, Christiane Hoffmann, Christian Rübe, Barbara Dockhorn-Dworniczak, Sebastian Blasius, Jürgen Dunst, Jörn Treuner, Herbert Jürgens, Winfried Winkelmann

*Corresponding author for this work
14 Citations (Scopus)


We reviewed the treatment outcome of 69 patient's with Ewing's sarcoma of the femur. The patients received chemotherapy according to the CESS 81 (n 14), CESS 86 (n 43), and CESS 91P (n 12) protocols. The 10-year relapse-free survival rates were 36%, 65%, and 65% (p = 0.01). 68 patients received local treatment. The primary tumor was treated by surgery without radiotherapy in 28 patients; 1 developed a local recurrence and 7 metastases. 10 patients received radiotherapy alone; 4 developed metastases and 4 local recurrences and metastases. 30 cases had a combination of surgery and radiotherapy; 7 developed metastases and 1 a local recurrence and metastasis. The survival of patients after radiotherapy alone was worse than that of patients after surgery with/without radiotherapy (p = 0.005). Pathological fractures (n 16) did not influence the prognosis.

Original languageEnglish
JournalActa Orthopaedica Scandinavica
Issue number1
Pages (from-to)20-24
Number of pages5
Publication statusPublished - 1997


Dive into the research topics of 'Ewing's sarcoma of the femur. Prognosis in 69 patients treated by the CESS group'. Together they form a unique fingerprint.

Cite this